No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration

US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.